Fate Therapeutics(FATE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

FATE Fate Therapeutics

Closed 04-23 16:00:00 EDT

4.54

-0.24

-5.02%

盘后4.54

+0.000.00%

17:09 EDT

High5.02	Low4.49	Vol4.02M
Open4.79	D1 Closing4.78	Amplitude11.19%
Mkt Cap516.73M	Tradable Cap419.96M	Total Shares113.82M
T/O18.68M	T/O Rate4.35%	Tradable Shares92.50M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"FATE","market":"US","secType":"STK","nameCN":"Fate Therapeutics","latestPrice":4.54,"timestamp":1713902400000,"preClose":4.78,"halted":0,"volume":4022308,"hourTrading":{"tag":"盘后","latestPrice":4.54,"preClose":4.54,"latestTime":"17:09 EDT","volume":41654,"amount":189107.17,"timestamp":1713906596139},"delay":0,"floatShares":92501638,"shares":113816708,"eps":-1.64,"marketStatus":"Closed","change":-0.24,"latestTime":"04-23 16:00:00 EDT","open":4.79,"high":5.02,"low":4.485,"amount":18684340.653132,"amplitude":0.111925,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.64,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1713945600000},"marketStatusCode":5,"adr":0,"adrRate":0,"listingDate":1380600000000,"exchange":"NASDAQ","adjPreClose":4.78,"preHourTrading":{"tag":"盘前","latestPrice":4.78,"preClose":4.78,"latestTime":"08:51 EDT","volume":174,"amount":853.3199424000001,"timestamp":1713876667092},"postHourTrading":{"tag":"盘后","latestPrice":4.54,"preClose":4.54,"latestTime":"17:09 EDT","volume":41654,"amount":189107.17,"timestamp":1713906596139},"volumeRatio":1.758974},"requestUrl":"/m/hq/s/FATE","defaultTab":"news","newsList":[{"id":"2429147113","title":"Fate Therapeutics, Inc.'s (NASDAQ:FATE) 28% Dip In Price Shows Sentiment Is Matching Revenues","url":"https://stock-news.laohu8.com/highlight/detail?id=2429147113","media":"Simply Wall St.","top":-1,"share":"https://ttm.financial/m/news/2429147113?lang=en_us&edition=fundamental","pubTime":"2024-04-24 03:23","pubTimestamp":1713900206,"startTime":"0","endTime":"0","summary":"Fate Therapeutics, Inc. ( NASDAQ:FATE ) shares have retraced a considerable 28% in the last month, reversing a fair...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-fate/fate-therapeutics/news/fate-therapeutics-incs-nasdaqfate-28-dip-in-price-shows-sent","is_publish_highlight":false,"gpt_icon":0},{"id":"2429145338","title":"Fate Therapeutics Currently Down 10 Consecutive Days, on Pace for Longest Losing Streak Since December 2022 -- Data Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2429145338","media":"Dow Jones","top":-1,"share":"https://ttm.financial/m/news/2429145338?lang=en_us&edition=fundamental","pubTime":"2024-04-24 02:09","pubTimestamp":1713895740,"startTime":"0","endTime":"0","summary":"Fate Therapeutics, Inc.  is currently at $4.58, down $0.21 or 4.29%. --Would be lowest close since Jan. 26, 2024, when it closed at $4.56. --Currently down 10 consecutive days; down 32.32% over this period. --Longest losing streak since Dec. 28, 2022, when it fell for 10 straight trading days. --Down 37.67% month-to-date; on pace for worst month since Aug. 2023, when it fell 39.23%. --Down 96.1% from its all-time closing high of $117.40 on Jan. 14, 2021. --Down 24.13% from 52 weeks ago , when it closed at $6.03. --Up 177.27% from its 52-week closing low of $1.65 on Oct. 27, 2023. --Traded as low as $4.49; lowest intraday level since Jan. 29, 2024, when it hit $4.43","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"gpt_icon":0},{"id":"2429906186","title":"Fate Therapeutics Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2429906186","media":"GlobeNewswire","top":-1,"share":"https://ttm.financial/m/news/2429906186?lang=en_us&edition=fundamental","pubTime":"2024-04-22 20:30","pubTimestamp":1713789000,"startTime":"0","endTime":"0","summary":"Key Therapeutic Mechanisms of Clinical Activity for Autoimmune Diseases, including B cell Depletion, Tissue Infiltration and Immune Reconstitution Data, from Phase 1 Study of FT819 in Relapsed / Refra","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/04/22/2867237/24675/en/Fate-Therapeutics-Announces-Presentation-of-FT819-Proof-of-Concept-Data-for-B-cell-mediated-Autoimmune-Diseases-at-ASGCT-Annual-Meeting.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2428542916","title":"Fate Therapeutics files to sell 3.64M shares for holders","url":"https://stock-news.laohu8.com/highlight/detail?id=2428542916","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2428542916?lang=en_us&edition=fundamental","pubTime":"2024-04-19 04:32","pubTimestamp":1713472327,"startTime":"0","endTime":"0","summary":"Fate Therapeutics  on Thursday filed a prospectus related to a proposed resale of about 3.64M shares of its common stock by selling stockholders.This prospectus is not an offer to sell these securities.More on Fate Therapeutics  Fate Therapeutics, Inc.  Q4 2023 Earnings Call Transcript Fate Therapeutics Update: A Rally Based On Little Increases Near-Term Risks Fate Therapeutics announces pricing of $100M underwritten offering and concurrent private placement Seeking Alpha’s Quant Rating on Fate Therapeutics Historical earnings data for Fate Therapeutics","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4091278-fate-therapeutics-files-to-sell-364m-shares-for-holders","is_publish_highlight":false,"gpt_icon":0},{"id":"2426232844","title":"Analysts Offer Insights on Healthcare Companies: Fate Therapeutics (FATE), Disc Medicine (IRON) and Avita Medical (RCEL)","url":"https://stock-news.laohu8.com/highlight/detail?id=2426232844","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2426232844?lang=en_us&edition=fundamental","pubTime":"2024-04-11 18:20","pubTimestamp":1712830816,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Fate Therapeutics (FATE – Research Report), Disc M...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-fate-therapeutics-fate-disc-medicine-iron-and-avita-medical-rcel?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-fate-therapeutics-fate-disc-medicine-iron-and-avita-medical-rcel?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2426425556","title":"FATE, ALPN and RLAY are among after hour movers","url":"https://stock-news.laohu8.com/highlight/detail?id=2426425556","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2426425556?lang=en_us&edition=fundamental","pubTime":"2024-04-11 05:20","pubTimestamp":1712784042,"startTime":"0","endTime":"0","summary":"Gainers:Rallybio Corporation (RLYB) +42%.Alpine Immune Sciences (ALPN) +36%.Vera Therapeutics (VERA) +10%.Relay Therapeutics (RLAY) +7%.Olema Pharmaceuticals (OLMA) +5%.Losers:Performant Financial (PFMT) -5%.Fate Therapeutics (FATE) -4%.SoundHound (SOUN) -3%.Hertz Global Holdings (HTZWW) -3%.NioCorp Developments (NB) -3%.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4088770-fate-alpn-and-rlay-are-among-after-hour-movers","is_publish_highlight":false,"gpt_icon":0},{"id":"2426198091","title":"Iovance Biotherapeutics: Riding The Favorable Moment Could Bring Excellent Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2426198091","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2426198091?lang=en_us&edition=fundamental","pubTime":"2024-04-09 18:05","pubTimestamp":1712657154,"startTime":"0","endTime":"0","summary":"Iovance Biotherapeutics is experiencing a favorable moment following FDA approval for its melanoma drug Amtagvi and a successful underwritten offering.The company has developed its own production capa","market":"us","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1487494602/image_1487494602.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1487494602/image_1487494602.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4682837-iovance-biotherapeutics-riding-the-favorable-moment-could-bring-excellent-results","is_publish_highlight":false,"gpt_icon":0},{"id":"2425957619","title":"Fate Therapeutics (FATE) Surges 86.4% YTD on Pipeline Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2425957619","media":"Zacks","top":-1,"share":"https://ttm.financial/m/news/2425957619?lang=en_us&edition=fundamental","pubTime":"2024-04-06 14:17","pubTimestamp":1712384220,"startTime":"0","endTime":"0","summary":"Fate Therapeutics’ FATE shares have surged 86.4% year to date compared with the industry’s growth of 1.5%. This can be attributed to the overall positive sentiment across the company’s innovative pipeline and recent pipeline progress.FATE is a clinical-stage biopharmaceutical company, building a pipeline of programmed cellular immunotherapies for cancer and autoimmune diseases. The company is using cell programming to create better cell therapies. It creates and engineers human induced pluripotent stem cells  to incorporate novel synthetic controls of cell function. FATE also generates a clonal master iPSC line for use as a renewable source of cell manufacture and directs the fate of the clonal master iPSC line to produce its cell therapy product candidate.The gross proceeds from the underwritten offering and private placement were $100.0 million, which will be used for funding clinical trials and other working capital and general corporate purposes. The influx of cash is a positive fo","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/Xa2Vc1PlR0VRosgCTc2fiw--~B/aD02MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/48b73c184482a4e70fafbb44589c8140","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/Xa2Vc1PlR0VRosgCTc2fiw--~B/aD02MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/48b73c184482a4e70fafbb44589c8140"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/fate-therapeutics-fate-surges-86-061700602.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2424814133","title":"Fate Therapeutics to Present at 23rd Annual Needham Virtual Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2424814133","media":"GlobeNewswire","top":-1,"share":"https://ttm.financial/m/news/2424814133?lang=en_us&edition=fundamental","pubTime":"2024-04-03 12:00","pubTimestamp":1712116800,"startTime":"0","endTime":"0","summary":"SAN DIEGO, April  03, 2024  (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/04/03/2856877/24675/en/Fate-Therapeutics-to-Present-at-23rd-Annual-Needham-Virtual-Healthcare-Conference.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2424907226","title":"Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2424907226","media":"StreetInsider","top":-1,"share":"https://ttm.financial/m/news/2424907226?lang=en_us&edition=fundamental","pubTime":"2024-04-03 04:01","pubTimestamp":1712088060,"startTime":"0","endTime":"0","summary":"SAN DIEGO, April 02, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.streetinsider.com/dr/news.php?id=23015552","is_publish_highlight":false,"gpt_icon":0},{"id":"2423497582","title":"Why Is Amicus Therapeutics (FOLD) Down 8.1% Since Last Earnings Report?","url":"https://stock-news.laohu8.com/highlight/detail?id=2423497582","media":"Zacks","top":-1,"share":"https://ttm.financial/m/news/2423497582?lang=en_us&edition=fundamental","pubTime":"2024-03-29 23:30","pubTimestamp":1711726233,"startTime":"0","endTime":"0","summary":"A month has gone by since the last earnings report for Amicus Therapeutics . Shares have lost about 8.1% in that time frame, underperforming the S&P 500.Will the recent negative trend continue leading up to its next earnings release, or is Amicus Therapeutics due for a breakout?Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts.Amicus reported fourth-quarter 2023 adjusted earnings of 1 cent per share against the Zacks Consensus Estimate of a loss of 6 cents. The company had reported a loss of 17 cents per share in the year-ago quarter.Revenues in the fourth quarter totaled $115.1 million, up 31% year over year on a reported basis. The figure matched the Zacks Consensus Estimate. The top line comprised sales of Galafold and Pombiliti + Opfolda. On a constant-currency  basis, total revenue growth was 27% year over year.Currently, Amicus Therapeutics h","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/7h8ntzJXcDOdVmDKQ08gRg--~B/aD02MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/e8e4b0344809eaac6d73c9fd25fd180a","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/7h8ntzJXcDOdVmDKQ08gRg--~B/aD02MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/e8e4b0344809eaac6d73c9fd25fd180a"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/why-amicus-therapeutics-fold-down-153033917.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2423448661","title":"Fate Therapeutics Is Maintained at Underperform by B of A Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2423448661","media":"Dow Jones","top":-1,"share":"https://ttm.financial/m/news/2423448661?lang=en_us&edition=fundamental","pubTime":"2024-03-29 02:24","pubTimestamp":1711650240,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/FATE/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 28, 2024 14:24 ET (18:24 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"gpt_icon":0},{"id":"2422715131","title":"Cautious Outlook on Fate Therapeutics: Sell Rating Maintained Amid Competitive and Validation Concerns","url":"https://stock-news.laohu8.com/highlight/detail?id=2422715131","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2422715131?lang=en_us&edition=fundamental","pubTime":"2024-03-28 16:58","pubTimestamp":1711616284,"startTime":"0","endTime":"0","summary":"Bank of America Securities analyst Tazeen Ahmad reiterated a Sell rating on Fate Therapeutics (FATE – Research Report) yesterday and set a price ta...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/cautious-outlook-on-fate-therapeutics-sell-rating-maintained-amid-competitive-and-validation-concerns?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/cautious-outlook-on-fate-therapeutics-sell-rating-maintained-amid-competitive-and-validation-concerns?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2422946492","title":"Fate Therapeutics (FATE) Down 8% Since Last Earnings Report: Can It Rebound?","url":"https://stock-news.laohu8.com/highlight/detail?id=2422946492","media":"Zacks","top":-1,"share":"https://ttm.financial/m/news/2422946492?lang=en_us&edition=fundamental","pubTime":"2024-03-27 23:30","pubTimestamp":1711553422,"startTime":"0","endTime":"0","summary":"A month has gone by since the last earnings report for Fate Therapeutics . Shares have lost about 8% in that time frame, underperforming the S&P 500.Will the recent negative trend continue leading up to its next earnings release, or is Fate Therapeutics due for a breakout?Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers.Fate Therapeutics Q4 Earnings Beat, Revenues Fall Y/Y. Fate Therapeutics reported fourth-quarter 2023 loss of 45 cents per share, narrower than the Zacks Consensus Estimate of a loss of 57 cents and the year-ago loss of 58 cents.The loss narrowed year over year due to lower R&D expenses.Earlier this month, the company was awarded $7.9 million by California Institute for Regenerative Medicine to support the clinical development of FT819 in patients with SLE. The phase I SLE study will evaluate the safety, pharmacokinetics and anti-B-c","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/UPInF06X6fJkTqeimnpZuQ--~B/aD03NDU7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/078b2d95159d12a337f09f2519ff10ba","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/UPInF06X6fJkTqeimnpZuQ--~B/aD03NDU7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/078b2d95159d12a337f09f2519ff10ba"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/fate-therapeutics-fate-down-8-153022851.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2422650730","title":"Analysts Offer Insights on Healthcare Companies: Fate Therapeutics (FATE) and AbbVie (ABBV)","url":"https://stock-news.laohu8.com/highlight/detail?id=2422650730","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2422650730?lang=en_us&edition=fundamental","pubTime":"2024-03-26 09:10","pubTimestamp":1711415428,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Fate Therapeutics (FATE – Research Report) and AbbVi...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-fate-therapeutics-fate-and-abbvie-abbv?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-fate-therapeutics-fate-and-abbvie-abbv?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2422757153","title":"WPRT, FIVN and FATE are among after hour movers","url":"https://stock-news.laohu8.com/highlight/detail?id=2422757153","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2422757153?lang=en_us&edition=fundamental","pubTime":"2024-03-26 05:15","pubTimestamp":1711401309,"startTime":"0","endTime":"0","summary":"Gainers:Stoke Therapeutics (STOK) +87%.AnaptysBio (ANAB) +8%.Amneal Pharmaceuticals (AMRX) +6%.Omega Therapeutics (OMGA) +5%.MoneyHero (MNY) +5%.Losers:Ocular Therapeutix (OCUL) -6%.Fate Therapeutics (FATE) -5%.Westport Fuel Systems (WPRT) -4%.Lexicon Pharmaceuticals (LXRX) -3%.Five9 (FIVN) -3%.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4083482-wprt-fivn-and-fate-are-among-after-hour-movers","is_publish_highlight":false,"gpt_icon":0},{"id":"2420217782","title":"Fate Therapeutics announces pricing of $100M underwritten offering and concurrent private placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2420217782","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2420217782?lang=en_us&edition=fundamental","pubTime":"2024-03-19 20:56","pubTimestamp":1710853018,"startTime":"0","endTime":"0","summary":"Fate Therapeutics  on Tuesday announced the pricing of an underwritten offering of 14,545,454 shares of its common stock at an offering price of $5.50 per share. The offering includes participation from new and existing institutional investors, including Adage Capital Partners, Boxer Capital among others.  In addition, the company announced the pricing of a concurrent private placement of pre-funded warrants to purchase 3,636,364 shares of its common stock at a purchase price of $5.499 per pre-funded warrant. The gross proceeds from the underwritten offering and private placement are expected to be about $100 million. All of the shares and pre-funded warrants are to be sold by the company. The financing is expected to close on or about March 21. FATE -0.56% premarket to $7.0. Source: Press Release    More on Fate Therapeutics  Fate Therapeutics Update: A Rally Based On Little Increases Near-Term Risks Seeking Alpha’s Quant Rating on Fate Therapeutics Historical earnings data for Fate T","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4081017-fate-therapeutics-announces-pricing-of-100m-underwritten-offering-and-concurrent-private-placement","is_publish_highlight":false,"gpt_icon":0},{"id":"2420324627","title":"Fate Therapeutics: A Hold Rating Amidst Financial Uncertainty and Clinical Milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=2420324627","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2420324627?lang=en_us&edition=fundamental","pubTime":"2024-03-19 18:28","pubTimestamp":1710844103,"startTime":"0","endTime":"0","summary":"Analyst Robert Burns of H.C. Wainwright reiterated a Hold rating on Fate Therapeutics (FATE – Research Report), with a price target of $7.00. Rober...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/fate-therapeutics-a-hold-rating-amidst-financial-uncertainty-and-clinical-milestones?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/fate-therapeutics-a-hold-rating-amidst-financial-uncertainty-and-clinical-milestones?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2420226913","title":"Fate Therapeutics Announces Pricing of $100 Million Underwritten Offering and Concurrent Private Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2420226913","media":"GlobeNewswire","top":-1,"share":"https://ttm.financial/m/news/2420226913?lang=en_us&edition=fundamental","pubTime":"2024-03-19 12:44","pubTimestamp":1710823440,"startTime":"0","endTime":"0","summary":"SAN DIEGO, March  19, 2024  (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/03/19/2848583/24675/en/Fate-Therapeutics-Announces-Pricing-of-100-Million-Underwritten-Offering-and-Concurrent-Private-Placement.html","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.fatetherapeutics.com","stockEarnings":[{"period":"1week","weight":-0.1525},{"period":"1month","weight":-0.2769},{"period":"3month","weight":-0.0104},{"period":"6month","weight":1.6556},{"period":"1year","weight":-0.2315},{"period":"ytd","weight":0.2781}],"compareEarnings":[{"period":"1week","weight":-0.0094},{"period":"1month","weight":-0.0412},{"period":"3month","weight":0.0306},{"period":"6month","weight":0.1968},{"period":"1year","weight":0.2123},{"period":"ytd","weight":0.0514}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma and FT522, to treat lymphoma and autoimmune disorders; and CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.545455,"avgChangeRate":0.058546},{"month":2,"riseRate":0.636364,"avgChangeRate":0.08272},{"month":3,"riseRate":0.545455,"avgChangeRate":0.019657},{"month":4,"riseRate":0.545455,"avgChangeRate":-0.044985},{"month":5,"riseRate":0.5,"avgChangeRate":-0.011757},{"month":6,"riseRate":0.6,"avgChangeRate":0.022155},{"month":7,"riseRate":0.4,"avgChangeRate":-0.000476},{"month":8,"riseRate":0.4,"avgChangeRate":0.007076},{"month":9,"riseRate":0.4,"avgChangeRate":-0.015658},{"month":10,"riseRate":0.2,"avgChangeRate":-0.084781},{"month":11,"riseRate":0.545455,"avgChangeRate":0.090798},{"month":12,"riseRate":0.636364,"avgChangeRate":0.109378}],"exchange":"NASDAQ","name":"Fate Therapeutics","nameEN":"Fate Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Fate Therapeutics(FATE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Fate Therapeutics(FATE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Fate Therapeutics,FATE,Fate Therapeutics股票,Fate Therapeutics股票老虎,Fate Therapeutics股票老虎国际,Fate Therapeutics行情,Fate Therapeutics股票行情,Fate Therapeutics股价,Fate Therapeutics股市,Fate Therapeutics股票价格,Fate Therapeutics股票交易,Fate Therapeutics股票购买,Fate Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Fate Therapeutics(FATE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Fate Therapeutics(FATE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}